Mesenchymal stromal cells and their derivatives – putative therapeutics in the management of autoimmune pancreatitis

Autoimmune pancreatitis, a derivative of chronic pancreatitis, frequently causes acute episodes with clinical symptoms parallel to those of acute pancreatitis. Corticosteroids are effective in the treatment of 90% of autoimmune pancreatitis cases, but for the remaining 10%, options are limited. Due...

Full description

Saved in:
Bibliographic Details
Published in:FEBS open bio 2020-06, Vol.10 (6), p.969-978
Main Authors: Goodman, Robbie R., Davies, John E.
Format: Article
Language:English
Subjects:
acute episodes
anti‐inflammatory
autoimmune pancreatitis
Bone marrow
Clinical trials
Corticosteroids
Cytokines
Diabetes
Disease
Edema
Genotype & phenotype
Immunomodulation
Inflammation
Licenses
Mesenchymal stem cells
mesenchymal stromal cells
Mesenchyme
MSC derivatives
MSC necrobiology
Pancreatitis
Regulatory approval
Review
Stem cells
Stromal cells
Tumor necrosis factor-TNF
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5626-6c7633fd9aaa6bbf497fbc3d2064d572932126921d1683e558fb71a1768449b33
cites cdi_FETCH-LOGICAL-c5626-6c7633fd9aaa6bbf497fbc3d2064d572932126921d1683e558fb71a1768449b33
container_end_page 978
container_issue 6
container_start_page 969
container_title FEBS open bio
container_volume 10
creator Goodman, Robbie R.
Davies, John E.
description Autoimmune pancreatitis, a derivative of chronic pancreatitis, frequently causes acute episodes with clinical symptoms parallel to those of acute pancreatitis. Corticosteroids are effective in the treatment of 90% of autoimmune pancreatitis cases, but for the remaining 10%, options are limited. Due to their significant immunomodulatory capabilities, mesenchymal stromal cells (MSCs) have been proposed as a novel treatment strategy for various immune and inflammatory pathologies including those with autoimmune origins. Here, we not only highlight the most recent MSC live‐cell experiments to address acute pancreatitis, but also discuss the opportunities afforded by the emergence of the newly identified field of MSC necrobiology. We conclude that the putative employment of MSC derivatives provides a newer and simpler therapeutic approach that could have significant advantages over the use of cells themselves. Autoimmune pancreatitis frequently causes acute episodes with clinical symptoms parallel to those of acute pancreatitis. Due to their significant immunomodulatory capabilities, mesenchymal stromal cells (MSCs) have been proposed as a novel treatment strategy for various immune and inflammatory pathologies including those with autoimmune origins. Here, we not only highlight the most recent MSC live‐cell experiments to address acute pancreatitis, but also discuss the opportunities afforded by the emergence of the newly identified field of MSC necrobiology.
doi_str_mv 10.1002/2211-5463.12866
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_642627db6ca148d7936a197a11c8c02d</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_642627db6ca148d7936a197a11c8c02d</doaj_id><sourcerecordid>2394261104</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5626-6c7633fd9aaa6bbf497fbc3d2064d572932126921d1683e558fb71a1768449b33</originalsourceid><addsrcrecordid>eNqFks9u1DAQxiMEolXpmRuyxIXLtv4XO74gQdVCpSIucLYmtrPrVRIHO9lqb7wDb8iT4GzKquWCfbBn5pufxtZXFK8JviAY00tKCVmVXLALQishnhWnx8zzR_eT4jylLc5LYCIwflmcMJo3F_K02H1xyfVms--gRWmMYT6Na9uEoLdo3DgfkXXR72D0O5fQ75-_0DCNh2guRxjcNHqTkO_nGHXQw9p1rh9RaBBMY_BdN_UODdCb6HLj6NOr4kUDbXLnD-dZ8f3m-tvV59Xd10-3Vx_uVqYUVKyEkYKxxioAEHXdcCWb2jBLseC2lFQxSqhQlFgiKubKsmpqSYBIUXGuasbOituFawNs9RB9B3GvA3h9SIS41hDz9K3TglNBpa2FAcIrKxUTQJQEQkxlMLWZ9X5hDVPdOWvyCyO0T6BPK73f6HXYaZnBipQZ8O4BEMOPyaVRdz7Nfw29C1PSlKk8AyGYZ-nbf6TbMMU-f5WmHEulsCSz6nJRmRhSiq45DkOwni2iZxPo2QT6YJHc8ebxG476v4bIArEI7n3r9v_j6Zvrj3wh_wG4N8dq</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2407990714</pqid></control><display><type>article</type><title>Mesenchymal stromal cells and their derivatives – putative therapeutics in the management of autoimmune pancreatitis</title><source>Wiley-Blackwell Open Access Collection</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Goodman, Robbie R. ; Davies, John E.</creator><creatorcontrib>Goodman, Robbie R. ; Davies, John E.</creatorcontrib><description>Autoimmune pancreatitis, a derivative of chronic pancreatitis, frequently causes acute episodes with clinical symptoms parallel to those of acute pancreatitis. Corticosteroids are effective in the treatment of 90% of autoimmune pancreatitis cases, but for the remaining 10%, options are limited. Due to their significant immunomodulatory capabilities, mesenchymal stromal cells (MSCs) have been proposed as a novel treatment strategy for various immune and inflammatory pathologies including those with autoimmune origins. Here, we not only highlight the most recent MSC live‐cell experiments to address acute pancreatitis, but also discuss the opportunities afforded by the emergence of the newly identified field of MSC necrobiology. We conclude that the putative employment of MSC derivatives provides a newer and simpler therapeutic approach that could have significant advantages over the use of cells themselves. Autoimmune pancreatitis frequently causes acute episodes with clinical symptoms parallel to those of acute pancreatitis. Due to their significant immunomodulatory capabilities, mesenchymal stromal cells (MSCs) have been proposed as a novel treatment strategy for various immune and inflammatory pathologies including those with autoimmune origins. Here, we not only highlight the most recent MSC live‐cell experiments to address acute pancreatitis, but also discuss the opportunities afforded by the emergence of the newly identified field of MSC necrobiology.</description><identifier>ISSN: 2211-5463</identifier><identifier>EISSN: 2211-5463</identifier><identifier>DOI: 10.1002/2211-5463.12866</identifier><identifier>PMID: 32323467</identifier><language>eng</language><publisher>England: John Wiley &amp; Sons, Inc</publisher><subject>acute episodes ; anti‐inflammatory ; autoimmune pancreatitis ; Bone marrow ; Clinical trials ; Corticosteroids ; Cytokines ; Diabetes ; Disease ; Edema ; Genotype &amp; phenotype ; Immunomodulation ; Inflammation ; Licenses ; Mesenchymal stem cells ; mesenchymal stromal cells ; Mesenchyme ; MSC derivatives ; MSC necrobiology ; Pancreatitis ; Regulatory approval ; Review ; Stem cells ; Stromal cells ; Tumor necrosis factor-TNF ; Vascular endothelial growth factor</subject><ispartof>FEBS open bio, 2020-06, Vol.10 (6), p.969-978</ispartof><rights>2020 The Authors. Published by FEBS Press and John Wiley &amp; Sons Ltd.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5626-6c7633fd9aaa6bbf497fbc3d2064d572932126921d1683e558fb71a1768449b33</citedby><cites>FETCH-LOGICAL-c5626-6c7633fd9aaa6bbf497fbc3d2064d572932126921d1683e558fb71a1768449b33</cites><orcidid>0000-0002-8733-0082</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2407990714/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2407990714?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,37013,44590,46052,46476,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32323467$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goodman, Robbie R.</creatorcontrib><creatorcontrib>Davies, John E.</creatorcontrib><title>Mesenchymal stromal cells and their derivatives – putative therapeutics in the management of autoimmune pancreatitis</title><title>FEBS open bio</title><addtitle>FEBS Open Bio</addtitle><description>Autoimmune pancreatitis, a derivative of chronic pancreatitis, frequently causes acute episodes with clinical symptoms parallel to those of acute pancreatitis. Corticosteroids are effective in the treatment of 90% of autoimmune pancreatitis cases, but for the remaining 10%, options are limited. Due to their significant immunomodulatory capabilities, mesenchymal stromal cells (MSCs) have been proposed as a novel treatment strategy for various immune and inflammatory pathologies including those with autoimmune origins. Here, we not only highlight the most recent MSC live‐cell experiments to address acute pancreatitis, but also discuss the opportunities afforded by the emergence of the newly identified field of MSC necrobiology. We conclude that the putative employment of MSC derivatives provides a newer and simpler therapeutic approach that could have significant advantages over the use of cells themselves. Autoimmune pancreatitis frequently causes acute episodes with clinical symptoms parallel to those of acute pancreatitis. Due to their significant immunomodulatory capabilities, mesenchymal stromal cells (MSCs) have been proposed as a novel treatment strategy for various immune and inflammatory pathologies including those with autoimmune origins. Here, we not only highlight the most recent MSC live‐cell experiments to address acute pancreatitis, but also discuss the opportunities afforded by the emergence of the newly identified field of MSC necrobiology.</description><subject>acute episodes</subject><subject>anti‐inflammatory</subject><subject>autoimmune pancreatitis</subject><subject>Bone marrow</subject><subject>Clinical trials</subject><subject>Corticosteroids</subject><subject>Cytokines</subject><subject>Diabetes</subject><subject>Disease</subject><subject>Edema</subject><subject>Genotype &amp; phenotype</subject><subject>Immunomodulation</subject><subject>Inflammation</subject><subject>Licenses</subject><subject>Mesenchymal stem cells</subject><subject>mesenchymal stromal cells</subject><subject>Mesenchyme</subject><subject>MSC derivatives</subject><subject>MSC necrobiology</subject><subject>Pancreatitis</subject><subject>Regulatory approval</subject><subject>Review</subject><subject>Stem cells</subject><subject>Stromal cells</subject><subject>Tumor necrosis factor-TNF</subject><subject>Vascular endothelial growth factor</subject><issn>2211-5463</issn><issn>2211-5463</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqFks9u1DAQxiMEolXpmRuyxIXLtv4XO74gQdVCpSIucLYmtrPrVRIHO9lqb7wDb8iT4GzKquWCfbBn5pufxtZXFK8JviAY00tKCVmVXLALQishnhWnx8zzR_eT4jylLc5LYCIwflmcMJo3F_K02H1xyfVms--gRWmMYT6Na9uEoLdo3DgfkXXR72D0O5fQ75-_0DCNh2guRxjcNHqTkO_nGHXQw9p1rh9RaBBMY_BdN_UODdCb6HLj6NOr4kUDbXLnD-dZ8f3m-tvV59Xd10-3Vx_uVqYUVKyEkYKxxioAEHXdcCWb2jBLseC2lFQxSqhQlFgiKubKsmpqSYBIUXGuasbOituFawNs9RB9B3GvA3h9SIS41hDz9K3TglNBpa2FAcIrKxUTQJQEQkxlMLWZ9X5hDVPdOWvyCyO0T6BPK73f6HXYaZnBipQZ8O4BEMOPyaVRdz7Nfw29C1PSlKk8AyGYZ-nbf6TbMMU-f5WmHEulsCSz6nJRmRhSiq45DkOwni2iZxPo2QT6YJHc8ebxG476v4bIArEI7n3r9v_j6Zvrj3wh_wG4N8dq</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Goodman, Robbie R.</creator><creator>Davies, John E.</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8733-0082</orcidid></search><sort><creationdate>202006</creationdate><title>Mesenchymal stromal cells and their derivatives – putative therapeutics in the management of autoimmune pancreatitis</title><author>Goodman, Robbie R. ; Davies, John E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5626-6c7633fd9aaa6bbf497fbc3d2064d572932126921d1683e558fb71a1768449b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>acute episodes</topic><topic>anti‐inflammatory</topic><topic>autoimmune pancreatitis</topic><topic>Bone marrow</topic><topic>Clinical trials</topic><topic>Corticosteroids</topic><topic>Cytokines</topic><topic>Diabetes</topic><topic>Disease</topic><topic>Edema</topic><topic>Genotype &amp; phenotype</topic><topic>Immunomodulation</topic><topic>Inflammation</topic><topic>Licenses</topic><topic>Mesenchymal stem cells</topic><topic>mesenchymal stromal cells</topic><topic>Mesenchyme</topic><topic>MSC derivatives</topic><topic>MSC necrobiology</topic><topic>Pancreatitis</topic><topic>Regulatory approval</topic><topic>Review</topic><topic>Stem cells</topic><topic>Stromal cells</topic><topic>Tumor necrosis factor-TNF</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goodman, Robbie R.</creatorcontrib><creatorcontrib>Davies, John E.</creatorcontrib><collection>Wiley-Blackwell Open Access Collection</collection><collection>Wiley-Blackwell Free Backfiles(OpenAccess)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>FEBS open bio</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goodman, Robbie R.</au><au>Davies, John E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mesenchymal stromal cells and their derivatives – putative therapeutics in the management of autoimmune pancreatitis</atitle><jtitle>FEBS open bio</jtitle><addtitle>FEBS Open Bio</addtitle><date>2020-06</date><risdate>2020</risdate><volume>10</volume><issue>6</issue><spage>969</spage><epage>978</epage><pages>969-978</pages><issn>2211-5463</issn><eissn>2211-5463</eissn><abstract>Autoimmune pancreatitis, a derivative of chronic pancreatitis, frequently causes acute episodes with clinical symptoms parallel to those of acute pancreatitis. Corticosteroids are effective in the treatment of 90% of autoimmune pancreatitis cases, but for the remaining 10%, options are limited. Due to their significant immunomodulatory capabilities, mesenchymal stromal cells (MSCs) have been proposed as a novel treatment strategy for various immune and inflammatory pathologies including those with autoimmune origins. Here, we not only highlight the most recent MSC live‐cell experiments to address acute pancreatitis, but also discuss the opportunities afforded by the emergence of the newly identified field of MSC necrobiology. We conclude that the putative employment of MSC derivatives provides a newer and simpler therapeutic approach that could have significant advantages over the use of cells themselves. Autoimmune pancreatitis frequently causes acute episodes with clinical symptoms parallel to those of acute pancreatitis. Due to their significant immunomodulatory capabilities, mesenchymal stromal cells (MSCs) have been proposed as a novel treatment strategy for various immune and inflammatory pathologies including those with autoimmune origins. Here, we not only highlight the most recent MSC live‐cell experiments to address acute pancreatitis, but also discuss the opportunities afforded by the emergence of the newly identified field of MSC necrobiology.</abstract><cop>England</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>32323467</pmid><doi>10.1002/2211-5463.12866</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-8733-0082</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2211-5463
ispartof FEBS open bio, 2020-06, Vol.10 (6), p.969-978
issn 2211-5463
2211-5463
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_642627db6ca148d7936a197a11c8c02d
source Wiley-Blackwell Open Access Collection; Publicly Available Content Database; PubMed Central
subjects acute episodes
anti‐inflammatory
autoimmune pancreatitis
Bone marrow
Clinical trials
Corticosteroids
Cytokines
Diabetes
Disease
Edema
Genotype & phenotype
Immunomodulation
Inflammation
Licenses
Mesenchymal stem cells
mesenchymal stromal cells
Mesenchyme
MSC derivatives
MSC necrobiology
Pancreatitis
Regulatory approval
Review
Stem cells
Stromal cells
Tumor necrosis factor-TNF
Vascular endothelial growth factor
title Mesenchymal stromal cells and their derivatives – putative therapeutics in the management of autoimmune pancreatitis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T18%3A39%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mesenchymal%20stromal%20cells%20and%20their%20derivatives%20%E2%80%93%20putative%20therapeutics%20in%20the%20management%20of%20autoimmune%20pancreatitis&rft.jtitle=FEBS%20open%20bio&rft.au=Goodman,%20Robbie%20R.&rft.date=2020-06&rft.volume=10&rft.issue=6&rft.spage=969&rft.epage=978&rft.pages=969-978&rft.issn=2211-5463&rft.eissn=2211-5463&rft_id=info:doi/10.1002/2211-5463.12866&rft_dat=%3Cproquest_doaj_%3E2394261104%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5626-6c7633fd9aaa6bbf497fbc3d2064d572932126921d1683e558fb71a1768449b33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2407990714&rft_id=info:pmid/32323467&rfr_iscdi=true